CCR2 and pancreatic ductal adenocarcinoma: Furthermore, small molecule inhibitors that target CXCR2 on neutrophils and CCR2 on macrophages have demonstrated the ability to enhance the chemotherapeutic effects in models of pancreatic ductal adenocarcinoma.